Erschienen in:
26.05.2021 | ASO Author Reflections
ASO Author Reflections: Managing Recurrent Pseudomyxoma Peritonei in 430 Patients After Complete Cytoreduction and HIPEC
verfasst von:
Nima Ahmadi, MBBS, BSc(Med) Hons, MS, FRACS, Brendan J. Moran, MB, BCh, FRCSI, MCh, Doc Med
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2021
Einloggen, um Zugang zu erhalten
Excerpt
Pseudomyxoma peritonei (PMP) is an uncommon peritoneal malignancy that predominantly arises from a perforated epithelial appendiceal neoplasm. Epithelial appendiceal neoplasms vary in a spectrum from low-grade mucinous neoplasms to adenocarcinoma with or without signet ring cells. Over the past 3 decades, the treatment of PMP, knowledge of tumor behavior, and understanding of tumor biology has developed significantly. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care in the treatment of PMP, with 5- and 10-year survival rates of 87.4% and 70.3%
1 if a complete cytoreduction (CC0 or CC1) is achievable. However, despite good survival data, 22–44% of patients develop recurrence.
2 Treatment options for these patients include an expectant approach, re-do CRS with or without HIPEC, and systemic chemotherapy with palliative intent. There is uncertainty as to the best approach in the treatment of a patient with recurrence after prior CRS and HIPEC due to the heterogeneous nature of this patient group. There are limited published reports on the treatment of recurrent PMP and reports often based on small numbers and case selection. …
